Combined Drug Strategy May Improve Survival Rates in Breast Cancer Patients With Brain Metastasis

Combined Drug Strategy May Improve Survival Rates in Breast Cancer Patients With Brain Metastasis
shutterstock_117502474Findings from a recent pre-clinical study published in the journal Molecular Cancer Therapeutics may offer a promising drug strategy to improve survival in patients with aggressive breast cancer who are diagnosed with brain metastasis. The study conducted by a leading research team at UNC Lineberger Comprehensive Cancer Center was the first to evaluate the efficacy of a combined drug treatment targeting triple negative breast cancer after it has metastasised to the brain, a particularly devastating condition for which there are very few treatment options. The team conducted a pre-clinical trial in mice with the future goal of testing the strategy in patients. “We are doing this pre-clinical work with the goal of ultimately bringing new treatment strategies to clinical trials,” said Carey Anders, MD, a UNC Lineberger member, co-director of the UNC Cancer Care Brain Metastases Specialty Clinic, an associate professor at the UNC School of Medicine, and the study’s principal investigator. “We anticipate translating this into the clinic through our multi-disciplinary brain metastases clinic here at UNC.” These specific tumors are hard to treat since they lack
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.